Ovarian cancer is a malignant neoplasm originating from ovarian cells. This disease is characterized by neoplastic cell growth that can spread to surrounding tissues and organs. Ovarian cancer can manifest itself in various forms and types, including epithelial cancer, stromal cancer, and germ cell cancer. One of the features of this disease is its high mortality rate, due to late detection and significant metastases at the time of diagnosis. Symptoms of ovarian cancer often remain unclear in the early stages, which worsens the prognosis and complicates treatment.
History of the disease and interesting historical facts
The history of ovarian cancer research goes back many centuries. The first mentions of ovarian diseases can be found in the works of ancient Greek doctors such as Hippocrates, who described tumor-like formations in the pelvic area. During the Middle Ages, attention to ovarian diseases was significantly reduced, but in the 19th century, with the development of pathological anatomy, interest in ovarian tumors increased. In 1886, French pathologist Charles Mikulczyk first described the histological features of ovarian cancer. However, a full understanding of ovarian tumors and their metastasis came only with the development of oncology in the 20th century.
Epidemiology
According to the World Health Organization, ovarian cancer is the 8th most common cancer in women. Every year, about 300,000 women worldwide are diagnosed with ovarian cancer. In Russia, the incidence rate is about 8-10 cases per 100,000 women per year, with an increase among older patients. According to recent studies, the 5-year survival rate after diagnosis is 46% in developed countries and 30% in developing countries, which emphasizes the importance of early diagnosis and a sophisticated approach to treatment.
Genetic predisposition to this disease
Genetic predisposition plays a significant role in the development of ovarian cancer. The main genes involved in the development of this disease are BRCA1 and BRCA2. Mutations in these genes increase the risk of developing ovarian cancer to 40-60% compared to the general population. In addition, there is a link between Li-Fraumenni syndrome and ovarian cancer, which is also associated with mutations in the TP53 genes. Other less studied genes, such as PTEN and MSH2, may also be involved in the pathogenesis.
Risk factors for the development of this disease
The occurrence of ovarian cancer is influenced by both genetic and environmental-social factors. The main risk factors include:
- Age: The risk increases with age, especially after age 50.
- Genetic predisposition: having a family history of ovarian or breast cancer.
- Personal medical history: history of other cancers, such as breast cancer.
- Suboptimal hormonal factors: long-term use of hormonal contraceptives or hormonal therapy without positive control.
- Endometriosis: Having endometriosis may increase your risk of developing ovarian cancer.
- Nutritional factors: Some studies suggest the impact of low fruit and vegetable intake.
Diagnosis of this disease
The main symptoms that patients should look out for include:
- Unexplained pain in the lower abdomen.
- Bowel dysfunction, such as constipation.
- A feeling of fullness or heaviness in the pelvic area.
- Menstrual cycle disorders.
- Loss of appetite and sudden weight loss.
Laboratory tests may include:
- Complete blood count for CA-125 levels, a marker for ovarian cancer.
- Hormonal tests to assess ovarian function.
Radiological examinations include:
- Ultrasound examination of the pelvic organs.
- Computed tomography or magnetic resonance imaging for a more detailed examination.
Other diagnostic methods, such as laparoscopy, may be used to obtain biopsy material. Differential diagnosis is important with other types of tumors and gynecological diseases.
Treatment
Treatment of ovarian cancer depends on the stage of the disease and can be complex. The main approaches include:
- Surgical treatment: removal of the tumor and affected tissue, often with removal of the ovaries and uterus.
- Pharmacological treatment: chemotherapy, usually platinum-based drugs and taxols are used.
- Targeted therapy: the use of specific drugs to modulate molecular mechanisms, such as PARP inhibitors.
- Immunotherapy: A relatively new field that studies stimulating the immune system to fight tumors.
List of drugs used to treat this disease
The main drugs used in the treatment of ovarian cancer include:
- Cisplatin.
- Carboplatin.
- Paclitaxel.
- Doxorubicin.
- Bevacizumab.
- Olaparib.
- Regorofenib.
Disease monitoring
Disease monitoring includes regular examinations, follow-up tests, and imaging to assess residual tumor volumes or possible recurrence. The prognosis for ovarian cancer detected early is better than for late-stage cancer. Complications may include recurrence of the disease, metastasis to other organs, and side effects from treatment.
Age-related features of the disease
Ovarian cancer is more common in women over 50. In childbearing age, its diagnosis is rare, although not excluded. In young women, the disease may manifest itself more aggressively. It is important to take into account the individual characteristics of each age period, since approaches to diagnosis and treatment may differ.
Questions and Answers
- What are the first symptoms of ovarian cancer? Early symptoms can be difficult to spot, but you should pay attention to digestive difficulties, lower abdominal pain, and irregular menstrual cycles.
- What are the main treatments for ovarian cancer? Treatment includes surgery, chemotherapy, targeted and immunotherapy depending on the stage and nature of the tumor.
- What is the role of genetics in the development of ovarian cancer? Inherited mutations in the BRCA1 and BRCA2 genes significantly increase the risk of developing this disease.
- How often should I be tested after treatment for ovarian cancer? It is generally recommended to have follow-up examinations every 3-6 months for the first two years, and then annually thereafter.
- What is the chance of ovarian cancer recurring? The likelihood of recurrence depends on the stage at initial diagnosis and can vary from 30% to 90% depending on individual factors.
